Endoscopic Quality Improvement System Study
A Prospective, Single-center Study Evaluating the Effectiveness of Endo.Adm in Improving the Quality of Gastrointestinal Endoscopy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Renmin Hospital of Wuhan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Endoscopist:
- Endoscopist with more than one year experience in gastrointestinal mirror operation;
- Willing to further improve endoscopic quality through Endo.Adm feedback;
- Ability to read, understand and sign informed consent; The investigator believes that the subject understands the flow of the clinical study and is willing and able to complete all research procedures and follow-up visits in conjunction with the research process.
Exclusion Criteria:
Endoscopist:
- Have participated in other clinical trials;
- Frequently attending in academic conference which is difficult to ensure the number of endoscopic operations;
- Endoscopist who were either not present for both parts (phase1 and phase2) of the study.
Patients:
Colonoscopy:
- Polyposis syndromes
- Lumen obstruction
- History of colorectal surgery
- History of colorectal surgery
Gastroscopy:
- Obstruction
- History of gastric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Control group
Endoscopists in control group were informed standard quality indicators requirements and the corresponding references during informed consent.
|
None feedback.
|
|
Experimental: Feedback group
Endoscopists in feedback group were informed standard quality indicators requirements and the corresponding references during informed consent.
In addition to the quality requirements, endoscopists randomized to feedback group received customized quality reports feedback from Endo.Adm weekly.
|
Endoscopists received quality report generated by Endo.Adm.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adenoma detection rate
Time Frame: 3 Months
|
ADR was calculated by dividing the total number of patients being detected adenomas by the number of colonoscopies.
|
3 Months
|
|
Gastric precancerous detection rate
Time Frame: 3 Months
|
GPCs detection rate was calculated by dividing the total number of patients being detected gastric precancerous by the number of gastroscopies.
|
3 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adcanced ADR
Time Frame: 3 months
|
Adcanced ADR was calculated by dividing the total number of patients being detected ≥10mm in size, or adenomas with histopathology of tubulovillous, villous, adenocarcinoma, or high-grade dysplasia by the number of colonoscopies.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EA-19-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.